Delaware Clinical and Translational Research ACCEL Program-Tracking and Eval Core

特拉华州临床和转化研究 ACCEL 项目跟踪和评估核心

• 批准号: 10437683
• 负责人: Susan Giancola
• 金额: $ 14.12万
• 依托单位: UNIVERSITY OF DELAWARE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-25 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10437683
• 关键词: Accountability; Accounting; Address; Adoption; Area; Centers of Research Excellence; Clinical; Clinical Research; Clinical and Translational Science Awards; Collaborations; Communication; Communities; Complex; Data; Data Collection; Decision Making; Delaware; Development; Effectiveness; Ensure; Evaluation; Feedback; Funding; Infrastructure; Institution; Knowledge; Leadership; Measures; Medical; Methodology; Modeling; Monitor; National Institute of General Medical Sciences; Outcome; Performance; Process; Productivity; Progress Reports; Reporting; Research; Research Infrastructure; Research Institute; Resource Sharing; Resources; Role; South Carolina; Standardization; Thinness; Time; Translational Research; United States National Institutes of Health; Universities; Update; Work; base; cost effectiveness; experience; flexibility; improved; inter-institutional; member; programs; quality assurance; success; synergism; theories; tool; wasting; web based interface

Abstract—Tracking & Evaluation (T&E) The Tracking and Evaluation (T&E) Key Component Activity (KCA) of the Delaware Clinical and Translational (DE-CTR) ACCEL Program will define and facilitate the ongoing success of this complex research infrastructure program. The major thrust of T&E activities will move beyond the initial accounting of research productivity, which has been high during the first four years of the program, and focus during the renewal period on new initiatives, the quality of integration among KCAs, and the overall impact of the ACCEL program. The Specific Aims of T&E are to: 1) Developmentally define metrics that guide data collection, analysis, and reporting for each KCA to aid ACCEL Lead- ership in directing program improvement, expansion and efficient use of resources; 2) Monitor and report progress towards KCA Specific Aims and overall program accomplishments delivered via standardized reports and real-time web-based interfaces; 3) Assure quality of T&E activities by monitoring processes and products, and by implementing process improvements to reduce errors and improve efficiency; and 4) Develop and share best practices in tracking and evaluation across institutions and in close partnership with other IDeA programs, including the National CTR Evaluators Group, and the South Carolina Clinical and Translational Research Institute (SCTR). To achieve these aims, in addition to the Overall ACCEL Specific Aims, we will utilize Liaisons representing each institution and each KCA. We will collect KCA-specific metrics that provide feedback to ACCEL members, leadership, advisory council members, and NIH staff. These evaluation data will define the degree to which we increase communication, expand interdisciplinary and inter-institutional collaborations, optimize decision-making, and facilitate resource-sharing. We will also address the degree to which ACCEL increases capacity in areas of need and opportunity, improves con- nections with the community, and expands collaborations and infrastructure to Delaware State University. Impor- tantly, during this renewal period we will enhance the role of T&E collaborators at the Medical University of South Carolina (MUSC). Their expertise will allow us to more effectively incorporate Results Based Accountability, Utili- zation Focused Evaluation, Developmental Evaluation Theory, and Lean Six Sigma methodology into T&E, and will facilitate adoption of CTSA-based initiatives. To ensure that the quality of feedback provided by T&E is consistently high and relevant to the needs of users and leadership, we will call upon the expertise of MUSC Liaisons to provide objective quality assurance of T&E activities. We anticipate, based the experience of ACCEL during this first funding period, that a continued focus on strengthening cross-institutional and cross-disciplinary efforts in our highly collab- orative culture will facilitate further effective program building and use of resources in support of clinical and transla- tional research that benefit the Delaware community.

摘要—跟踪与评估 (T&E) 特拉华州临床和转化的跟踪和评估 (T&E) 关键组件活动 (KCA) (DE-CTR) ACCEL 计划将定义并促进这一复杂研究基础设施的持续成功 程序。 T&E 活动的主要目标将超越对研究生产力的初步核算， 在该计划的前四年中一直处于高水平，并在更新期间重点关注新举措， KCA 之间的整合质量，以及 ACCEL 计划的总体影响。 T&E 的具体目标是： 1) 以发展的方式定义指导每个 KCA 的数据收集、分析和报告的指标，以帮助 ACCEL Lead- 指导计划改进、扩展和有效利用资源的能力； 2) 监控并报告进度 通过标准化报告和实时报告实现 KCA 的具体目标和总体计划成就 基于网络的界面； 3) 通过监控过程和产品以及实施来确保 T&E 活动的质量 流程改进以减少错误并提高效率； 4) 开发并分享跟踪方面的最佳实践 跨机构的评估和评估，并与其他 IDeA 项目（包括国家 CTR）密切合作 评估小组和南卡罗来纳州临床与转化研究所 (SCTR)。为了实现这些 目标，除了总体 ACCEL 具体目标外，我们将利用代表每个机构和每个机构的联络员 韩国CA。我们将收集 KCA 特定指标，为 ACCEL 成员、领导层、咨询委员会提供反馈 成员和 NIH 工作人员。这些评估数据将定义我们增加沟通、拓展业务的程度 跨学科、跨机构合作，优化决策，促进资源共享。 我们还将讨论 ACCEL 在需求和机会领域提高能力的程度，提高 CON- 与社区的联系，并将合作和基础设施扩展到特拉华州立大学。进口- 总之，在更新期间，我们将加强南方医科大学 T&E 合作者的作用 卡罗莱纳州（MUSC）。他们的专业知识将使我们能够更有效地整合基于结果的问责制、效用 将聚焦评估、发展评估理论和精益六西格码方法引入 T&E，并将 促进基于 CTSA 的举措的采用。确保 T&E 提供的反馈质量始终如一 与用户和领导层的需求高度相关，我们将利用 MUSC 联络人的专业知识来提供 T&E 活动的客观质量保证。根据 ACCEL 在首次融资期间的经验，我们预计 在此期间，我们高度协作，继续注重加强跨机构和跨学科的努力 演讲文化将促进进一步有效的计划建设和资源利用，以支持临床和翻译 有益于特拉华州社区的国际研究。